Written by:
JORGE A. GUZMAN, MD
Director, Medical Intensive Care Unit
Cleveland Clinic Foundation


Jorge A. Guzman, MD, has indicated to Physician’s Weekly that he has received grants/research aid from bioMerieux, speakers fees for bioMeriuex, and consulting fees for Pfizer.

Written for Physician’s Weekly.

Sepsis is a potentially fatal condition that strikes an estimated 750,000 people each year in the United States. Defined as the body’s reaction to infection (whether bacterial, viral, fungal, or parasitic), sepsis is the most common underlying cause of mortality in non-coronary ICUs. It can rapidly lead to systemic inflammatory reactions and, eventually, organ dysfunction or failure. People who are at greatest risk of developing sepsis include patients who are very young or very old, those with compromised immune systems, those who are hospitalized and are very sick, and individuals with invasive devices (eg, urinary catheters or breathing tubes).
Continue Reading

German scientists came up with the discovery of a new biomarker which could be controlled to assess a response to chemotherapy of colorectal cancer. Indication of methylation of transcription factor AP-2 epsilon (TFAP2E) gens can be useful medical examination, helping to determine a chemotherapy resistance. (1,2) Read full text »